Compare Cigna Corp (CI) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Entegris Inc — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Entegris Inc trades at $151.9 (market cap $23.24B). The key difference: Cigna Corp is far larger — about 3.2× Entegris Inc's market cap, and Cigna Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| CI | ENTG | |
|---|---|---|
Market Cap | $73.56B | $23.24B |
Sector | Health | Technology |
52-Week High | $311.00 | $184.00 |
52-Week Low | $244.41 | $68.80 |
Enterprise Value | $98.27B | $26.44B |
Dividend Yield | 2.24% | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
ENTG is trading at $152.08, up 6.61% over 24 hours, near its consensus price target of $181.17. The stock shows bullish momentum with strong earnings beats in recent quarters, driven by AI-related semiconductor demand. Technical indicators suggest a bullish trend, though RSI hints at overbought conditions. Revenue growth and margin expansion are supported by increasing chip complexity and purity solutions demand.
Outlook remains positive with analyst consensus favoring Buy (66.67%), but high valuation multiples like P/E of 76.04 pose risks. Key opportunities include sustained AI-driven growth, while risks involve valuation sensitivity and semiconductor cycle volatility. The company's cash flow stability and strategic positioning in advanced segments support long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
